05.01.10
Nutraceutical: Vitamins C and E
Indication: Preeclampsia
Source: N Engl J Med, April 8, 2010;362 (14):1282-91.
Research: Researchers assessed the effects of antioxidant supplementation with vitamins C and E, initiated early in pregnancy, on the risk of serious adverse maternal, fetal and neonatal outcomes related to pregnancy-associated hypertension. They conducted a multicenter, randomized, double-blind trial involving 10,154 women who were at low risk for preeclampsia and had never given birth. Women were randomly assigned to begin daily supplementation with 1000 mg of vitamin C and 400 IU of vitamin E or matching placebo between the 9th and 16th weeks of pregnancy. The primary outcome was severe pregnancy-associated hypertension alone or severe or mild hypertension with elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, medically indicated preterm birth, fetal-growth restriction or perinatal death.
Results: The two groups were similar with respect to baseline characteristics and adherence to the study drug. There was no significant difference between the vitamin and placebo groups in the rates of the primary outcome or in the rates of preeclampsia. Researchers believe vitamin C and E supplementation initiated in the 9th to 16th week of pregnancy did not reduce the rate of adverse maternal or perinatal outcomes related to pregnancy-associated hypertension.
Indication: Preeclampsia
Source: N Engl J Med, April 8, 2010;362 (14):1282-91.
Research: Researchers assessed the effects of antioxidant supplementation with vitamins C and E, initiated early in pregnancy, on the risk of serious adverse maternal, fetal and neonatal outcomes related to pregnancy-associated hypertension. They conducted a multicenter, randomized, double-blind trial involving 10,154 women who were at low risk for preeclampsia and had never given birth. Women were randomly assigned to begin daily supplementation with 1000 mg of vitamin C and 400 IU of vitamin E or matching placebo between the 9th and 16th weeks of pregnancy. The primary outcome was severe pregnancy-associated hypertension alone or severe or mild hypertension with elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, medically indicated preterm birth, fetal-growth restriction or perinatal death.
Results: The two groups were similar with respect to baseline characteristics and adherence to the study drug. There was no significant difference between the vitamin and placebo groups in the rates of the primary outcome or in the rates of preeclampsia. Researchers believe vitamin C and E supplementation initiated in the 9th to 16th week of pregnancy did not reduce the rate of adverse maternal or perinatal outcomes related to pregnancy-associated hypertension.